Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: STD Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

NCT05664802
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
Behavioral
Lead sponsor
Northern Arizona University
Other
Eligibility
17 Years to 29 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

NCT00002007
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Zidovudine, Sargramostim
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional

Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms

NCT00000707
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 11:13 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional

Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART

NCT00386971
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
L-carnitine, placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 18, 2026, 11:13 AM EDT
Not listed Phase 4 Interventional

Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection

NCT04240509
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Emtricitabine / Tenofovir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 4 Interventional

Nutrition Intervention in AIDS Wasting

NCT00006167
View directory record Official record
Conditions
HIV Wasting Syndrome
Interventions
oxandrolone, Progressive Resistance Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507
View directory record Official record
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

NCT00490412
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

NCT00001000
View directory record Official record
Conditions
HIV Infections
Interventions
Ampligen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1990
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 2 Interventional

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra
Drug
Lead sponsor
Therapeutic Concepts
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK706769/KALETRA Drug-drug Interaction Study

NCT00723775
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK706769 & KALETRA
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

NCT01185028
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Nitazoxanide With Pegylated Interferon And Ribavirin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002407
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

NCT01467531
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Interventions
Dolutegravir, Rlipivirine, GSK1265744
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional Results available

Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting

NCT07498153
View directory record Official record
Conditions
Syphilis, HIV Infections
Interventions
Chembio HIV/Syphilis rapid POC test
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 65 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 4 Interventional Results available

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

NCT01102972
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 18, 2026, 11:13 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MR Imaging and MR Spectroscopy of HIV

NCT05219279
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

NCT02495779
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
emtricitabine/tenofovir, CBT-based counseling
Drug · Behavioral
Lead sponsor
James Egan
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania

NCT01865383
View directory record Official record
Conditions
Sexually Transmitted Infections, Domestic Violence
Interventions
Microfinance and Health Leadership
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 99 Years
Enrollment
2,623 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 2 Interventional

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

NCT00002154
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Thioctic acid, Selegiline hydrochloride
Drug
Lead sponsor
The Dana Foundation
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 11:13 AM EDT
Completed Phase 1 Interventional

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

NCT00623259
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-mBN120B
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2010 · Synced Oct 18, 2026, 11:13 AM EDT
Completed No phase listed Observational

Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients

NCT01507142
View directory record Official record
Conditions
AIDS/HIV PROBLEM
Interventions
Not listed
Lead sponsor
Gaia Medical Institute
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 18, 2026, 11:13 AM EDT